ASX Announcements

ASX Announcements

Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising.

Date Title  
29 November 2021 Results of Meeting
29 November 2021 CEO Presentation to 2021 Annual General Meeting
29 November 2021 Mesoblast Chairman Message to 2021 AGM
24 November 2021 MSB Q1 Financial Results and Operational Highlights
24 November 2021 First Quarter Results Presentation
24 November 2021 First Quarter Financial Results on Form 6-K
23 November 2021 Mesoblast Q1 Financial Results Webcast
22 November 2021 MSB and Oaktree Conclude Refinancing of Senior Debt Facility
22 November 2021 Proposed issue of securities - MSB
15 November 2021 AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
29 October 2021 Annual Report to Shareholders
29 October 2021 Notice of Annual General Meeting and Proxy Form
29 October 2021 Appendix 4G and Corporate Governance Statement
29 October 2021 Appendix 4C Quarterly Activity Report
18 October 2021 Remestemcel-L Improves Survival in High-Risk Acute GvHD
14 October 2021 Notification of cessation of securities - MSB
14 October 2021 Notification regarding unquoted securities - MSB
07 October 2021 CHF Late Breaker Presentation at American Heart Association
31 August 2021 MSB Annual Financial Results and Operational Progress
31 August 2021 Annual Financial Results Presentation
31 August 2021 Preliminary Final Report including Appendix 4E
30 August 2021 Appendix 3G and 3H
30 August 2021 Mesoblast 2021 Full Year Financial Results Webcast
10 August 2021 Mesoblast Management Update
30 July 2021 Appendix 4C Quarterly Activity Report
29 July 2021 Release of Shares from Voluntary Escrow
19 July 2021 COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT
16 July 2021 COVID ARDS Trial Respiratory Outcomes Presented
16 July 2021 COVID ARDS Trial Results Presentation
14 July 2021 Appendix 3Y - Change of Director's Interest Notice
07 July 2021 Appendix 3G
01 July 2021 Mesoblast Update on Chronic Low Back Pain Program
03 June 2021 MSB Reports Q3 Financial Results and Operational Highlight
03 June 2021 Third Quarter Results Presentation
03 June 2021 Third Quarter Financial Results on Form 6-K
03 June 2021 Mesoblast Q3 Financial Results Webcast
25 May 2021 Remestemcel-L for COPD Published in Respiratory Research
30 April 2021 COVID ARDS Trial Topline 60-Day Results
30 April 2021 Appendix 4C Quarterly Activity Report
30 April 2021 Mesoblast Corporate Update Webcast
06 April 2021 Director's Interest Notice - Appendix 3X
31 March 2021 Mesoblast Operational Highlights and Upcoming Milestones
29 March 2021 Director Appointment/Resignation
29 March 2021 Director Appointment/Resignation
15 March 2021 Prospectus for Warrants in Connection with US$110M Raise
09 March 2021 MSB Closes US$110M Raise Led By US Strategic Investor Group
09 March 2021 Cleansing Notice and Appendix 2A
03 March 2021 Cleansing Notice and Appendix 2A
02 March 2021 Proposed issue of Securities - MSB
02 March 2021 Mesoblast Raises US$110M Led By US Strategic Investor Group
26 February 2021 Half Year Report and Accounts (including Appendix 4D)
26 February 2021 Trading Halt
17 February 2021 Remestemcel-L for COVID-19 MIS-C published in Pediatrics
11 February 2021 Mesoblast Phase 3 Chronic Low Back Pain Results
11 February 2021 Mesoblast Corporate Update Webcast
29 January 2021 Appendix 4C Quarterly Activity Report
12 January 2021 CHF Phase 3 Trial Results Presented at Investor Conference
12 January 2021 Mesoblast Healthcare Conference Investor Presentation
11 January 2021 Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF

Share Price :    as of Nov 03, 2021